Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis

Critical Care Medicine

Volumn 26, Issue 5, 1998, Pages 895-904

  Remick, Daniel G ^a,b   Garg, Sunir J ^a   Newcomb, David E ^a   Wollenberg, Gordon ^a   Huie, Thomas K ^a   Bolgos, Gerald L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bacteria; Cytokines; In vivo animal models; Infectious immunity; Inflammation

Indexed keywords

INTERLEUKIN 6; MYELOPEROXIDASE; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; FEMALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; LIGATION; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED BALB C; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031954179     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199805000-00025     Document Type: Article

References (58)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine [see comments]. Chest 1992; 101:1644-1655
2. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477
3. Beutler BA: Orchestration of septic shock by cytokines: the role of cachectin (tumor necrosis factor). Prog Clin Biol Res 1989; 286:219-235
4. Grau GE, Piguet PF, Vassalli P, et al: Involvement of tumour necrosis factor and other cytokines in immune-mediated vascular pathology. Int Arch Allergy Appl Immunol 1989; 88:34-39
5. Brown JM, Grosso MA, Harken AH: Cytokines, sepsis and the surgeon. Surg Gynecol Obstet 1989; 169:568-575
6. de Waal Malefyt R, Abrams J, Bennett B, et al: Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220
7. Fiorentino DF, Zlotnik A, Mosmann TR, et al: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-3822
8. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
9. Oswald IP, Wynn TA, Sher A, et al: Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for Interferon gamma-induced activation. Proc Natl Acad Sci U S A 1992; 89:8676-8680
10. Gerard C, Bruyns C, Marchant A, et al: Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-550
11. Baker CC, Chaudry IH, Gaines HO, et al: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983; 94:331-335
12. Eskandari MK, Bolgos G, Miller C, et al: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-2730
13. Remick D, Manohar P, Bolgos G, et al: Blockade of tumor necrosis factor reduces lipopolysaccharie lethality, but not the lethality of cecal ligation and puncture. Shock 1995; 4:89-95
14. Echtenacher B, Falk W, Mannel DN, et al: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-3766
15. Wollenberg GK, DeForge LE, Bolgos G, et al: Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 1993; 143:1121-1130
16. Eskandari MK, Nguyen DT, Kunkel SL, et al: WEHI 164 subclone 13 assay for TNF: Sensitivity, specificity, and reliability, Immunological Investigations 1990; 19:69-79
17. Aarden LA, De Groot ER, Schaap OL, et al: Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17:1411-1416
18. DeForge LE, Takeuchi E, Nguyen DT, et al: Immunological priming attenuates the in vivo pathophysiological response to lipopolysaccharide. Comparison of cytokine production, tissue injury, and lethality in complete Freund's adjuvant-primed mice and in unprimed mice. Am J Pathol 1994; 144:599-611
19. Frevert CW, Huang S, Danaee H, et al: Functional characterization of the rat chemokine KC and its imporance in neutrophil recruitment in a rat model of pulmonary inflammation. J Immunol 1995; 154:335-344
20. Nguyen DT, Eskandari MK, DeForge LE, et al: Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J Immunol 1990; 144:3822-3828
21. DeForge LE, Remick DG: Sandwich ELISA for detection of picogram quantities of interleukin-8. Immunological Investigations 1991; 20:89-97
22. DeForge LE, Preston AM, Takeuchi E, et al: Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem 1993; 268:12-13
23. Remick DG, Strieter RM, Eskandari MK et al: Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am J Pathol 1990; 136:49-60
24. Goldblum SE, Wu KM, Jay M: Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985; 59:1978-1985
25. Howard M, Muchamuel T, Andrade S, et al: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-1208
26. Werner U, Szelenyi I: Measurement of MPO activity as model for detection of granulocyte infiltration in different tisues. Agents Actions 1992; Spec No:C101-C103
27. Shanley TP, Schmal H, Friedl HP, et al: Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J Immunol 1995; 154:3454-3460
28. Pennington JE: Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 1993; 17(Suppl 2):S515-519
29. Bean AG, Freiberg RA, Andrade S, et al: Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993; 61:4937-4939
30. Marchant A, Bruyns C, Vandenabeele P, et al: Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24:1167-1171
31. Standiford TJ, Strieter RM, Lukacs NW, et al: Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995; 155:2222-2229
32. Arai T, Hiromatsu K, Nishimura H, et al: Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection. Immunology 1995; 85:381-388
33. Florquin S, Amraoui Z, Abramowicz D, et al: Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol 1994; 153:2618-2623
34. Rogy MA, Auffenberg T, Espat NJ, et al: Human tumor necrosis factor re ceptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 1995; 181:2289-2293
35. Zheng XX, Steele AW, Nickerson PW, et al: Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154:5590-5600
36. Berg DJ, Kuhn R, Rajewsky K, et al: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96:2339-2347
37. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
38. Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-1561
39. Fischer E, Marano MA, Van Zee KJ, et al: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-1557
40. Aiura K, Gelfand JA, Burke JF, et al: Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun 1993; 61:3342-3350
41. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
42. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
43. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843
44. Kato T, Murata A, Ishida H, et al: Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother 1995; 39:1336-1340
45. van dor Poll T, Marchant A, Buurman WA, et al: Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995; 155:5397-5401
46. Vieth M, Will A, Schroppel K, et al: Interleukin-10 inhibits antimicrobial activity against Leishmania major in murine macrophages. Scand J Immunol 1994; 40:403-409
47. Fernandes DM and Baldwin CL: Interleukin-10 downregulates protective immunity to Brucella abortus. Infect Immun 1995; 63:1130-1133
48. Fleming SD, Campbell PA: Macrophages have cell surface IL-10 that regulates macrophage bactericidal activity. J Immunol 1996; 156:1143-1150
49. Tonnetti L, Spaccapelo R, Cenci E, et al: Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol 1995; 25:1559-1565
50. Kelly JP, Bancroft GJ: Administration of interleukin-10 abolishes innate resistance to Listeria monocytogenes. Eur J Immunol 1996; 26:356-364
51. Greenberger MJ, Strieter RM, Kunkel SL, et al: Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995; 155:722-729
52. Romani L, Puccetti P, Mencacci A, et al: Neutralization of IL-10 up-reglates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol 1994; 152:3514-3521
53. Wagner RD, Maroushek NM, Brown JF, et al: Treatment with anti-interleukin-10 monoclonal antibody enhances early resistance to but impairs complete clearance of Listeria monocytogenes infection in mice. Infect Immun 1994; 62:2345-2353
54. Lehmann AK, Halstensen A, Sornes S, et al: High levels of interleukin-10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63:2109-2112
55. Marchant A, Alegre ML, Hakim A, et al: Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15:266-273
56. Bagby GJ, Plessala KJ, Wilson LA, et al: Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-88
57. Porteu F, Nathan C: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172:599-607
58. Engelberts I, Stephens S, Francot GJ, et al: Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338:515-516